Sanofi's BTK inhibitor is declared for market in China
我放心你带套猛
发表于 2024-12-31 17:41:02
247
0
0
New Beijing News (Reporter Zhang Zhaohui) On December 30th, the official website of the Drug Evaluation Center of the National Medical Products Administration announced that the application for the listing of Class 1 new drug rilzbrutinib tablets jointly submitted by Sanofi and Genzyme has been accepted.
Public information shows that rilzabrutinib is an oral, reversible covalent BTK inhibitor that can selectively inhibit BTK targets while potentially reducing the risk of off target side effects. In November of this year, Sanofi announced the positive results of its Phase 3 clinical trial for indications of immune thrombocytopenia (ITP) at the American Society of Hematology (ASH) annual meeting. Sanofi previously stated that rilzabrutinib has the potential to become the first BTK inhibitor for the treatment of ITP indications. The product is currently undergoing regulatory review in the United States and the European Union.
This therapy has also been granted fast track and orphan drug status by the US FDA for the treatment of ITP. In addition to the indications for ITP, the product is also undergoing phase 2 clinical trials for chronic spontaneous urticaria, asthma, IgG4 related diseases, warm antibody type autoimmune hemolytic anemia, and other conditions.
LogoMoney.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表LogoMoney.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表LogoMoney.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Honda accelerates its electrification layout in China, with joint ventures intensively deploying electric vehicles
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Nvidia expands in China against the trend, attracting talent and adding hundreds of R&D personnel in one year
- Apple is rumored to have preliminary discussions with Tencent and ByteDance to consider embedding their AI models into iPhones sold in China
-
工信部党组书记李乐成会见德国汽车工业协会主席希尔德加德·穆勒 4月27日,工业和信息化部党组书记李乐成在北京会见德国汽车工业协会主席希尔德加德·穆勒,双方就深化中德汽车产业合作进行了交流。李乐成表 ...
- moonlightplay
- 前天 10:42
- 支持
- 反对
- 回复
- 收藏
-
美国总统特朗普近日在接受媒体采访时表示,他第二个任期不仅治理美国,也治理全世界。 特朗普于4月24日接受了《大西洋》(The Atlantic)月刊采访,这段专访于4月28日发布。 “第一次当总统时,我要做两 ...
- lfancn
- 1 小时前
- 支持
- 反对
- 回复
- 收藏
-
4月29日凌晨,阿里巴巴开源新一代通义千问模型Qwen3(千问3),参数量为DeepSeek-R1的三分之一,成本大幅下降。据称,该模型性能全面超越R1、OpenAI-o1等领先模型,登顶全球最强开源模型。 千问3是国内首个“ ...
- 风雨中行走
- 昨天 10:32
- 支持
- 反对
- 回复
- 收藏
-
东风有限回应武汉工厂关停事宜 据第一财经,4月29日,东风汽车有限公司证实,该公司武汉工厂目前正常运行,后续也不会关停。东风有限称,该公司将在东风与日产母公司的支持下平稳有序发展,持续加速向新能源 ...
- king19831101
- 3 小时前
- 支持
- 反对
- 回复
- 收藏